eXIthera Pharmaceutical

eXIthera Pharmaceutical Develops Novel, Potent, Selective Small Molecule Inhibitors Aimed at Preventing Thrombosis with Limited Risk of Bleeding Side Effects and No Need for Reversal Agents. The Company’s Platform Focuses on Developing Stroke Prevention and Antithrombotic Drugs That Play a Pathophysiological Role in the Initiation of Intravascular Thrombosis Without Causing Excessive Bleeding, Enabling Physicians to Treat Severe Consequences of Venous Thromboembolism, Deep Vein Thrombosis, Stroke, and Heart Attack.